The Scientific World Journal

The Scientific World Journal / 2002 / Article

Review Article | Open Access

Volume 2 |Article ID 324801 |

Martin H. Steinberg, "Hydroxyurea Treatment for Sickle Cell Disease", The Scientific World Journal, vol. 2, Article ID 324801, 23 pages, 2002.

Hydroxyurea Treatment for Sickle Cell Disease

Received01 Mar 2002
Accepted05 Apr 2002


High fetal hemoglobin (HbF) levels inhibit the polymerization of sickle hemoglobin (HbS) and reduce the complications of sickle cell disease. Pharmacologic agents that can reverse the switch from γ- to β-chain synthesis — γ-globin chains characterize HbF, and sickle β-globin chains are present in HbS — or selectively increase the proportion of adult erythroid precursors that maintain the ability to produce HbF are therapeutically useful. Hydroxyurea promotes HbF production by perturbing the maturation of erythroid precursors. This treatment increases the total hemoglobin concentration, reduces the vaso-occlusive complications of pain and acute chest syndrome, and attenuates mortality in adults. It is a promising beginning for pharmacologic therapy of sickle cell disease. Still, its effects are inconsistent, trials in infants and children are ongoing, and its ultimate value — and peril — when started early in life are still unknown.

More related articles

 PDF Download Citation Citation
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.